Unlike in MDS, in the ICC classification, a single TP53 mutation with VAF > 10% is sufficient to define AML with TP53 mutations (>20% blasts) or MDS/AML with TP53 mutation (10–19%) [2,47]. This evidence concerns the gene TP53 and intrahepatic cholangiocarcinoma.